CAJ | 학술논문

目的探讨乳腺印戒细胞癌的临床及病理特征.方法对17例乳腺印戒细胞癌(signet ring cell carcinoma,SRCC)患者的临床及病理资料进行回顾性分析.结果乳腺SRCC约占同期乳腺癌患者的2％～4.5％.10例患者就诊时伴淋巴结转移(58.8％),雌激素受体、孕激素受体阳性率分别为71.4％ (10/14)、64.9％ (9/14).7例患者于随访8个月～11年出现复发或转移,中位随访时间为40.5个月,3例患者入院时已伴远处转移.9例出现复发或转移的患者中,8例患者出现骨转移(88.9％),其中椎体转移6例(66.7％).乳腺SRCC患者治疗方式与同期乳腺癌相同,16例患者行手术治疗,14例患者同时接受化疗.其3年、5年无病生存率分别为53.0％(7/17)、23.0％(5/17).平均随访53个月,死亡率为41.2％ (7/17).结论乳腺印戒细胞癌侵袭性强,受体阳性率高,且治疗后易出现复发转移,预后差.
목적 탐토유선인계세포암적림상급병리특정.방법 대17례유선인계세포암(signet ring cell carcinoma,SRCC)환자적림상급병리자료진행회고성분석.결과 유선SRCC약점동기유선암환자적2％～4.5％.10례환자취진시반림파결전이(58.8％),자격소수체、잉격소수체양성솔분별위71.4％ (10/14)、64.9％ (9/14).7례환자우수방8개월～11년출현복발혹전이,중위수방시간위40.5개월,3례환자입원시이반원처전이.9례출현복발혹전이적환자중,8례환자출현골전이(88.9％),기중추체전이6례(66.7％).유선SRCC환자치료방식여동기유선암상동,16례환자행수술치료,14례환자동시접수화료.기3년、5년무병생존솔분별위53.0％(7/17)、23.0％(5/17).평균수방53개월,사망솔위41.2％ (7/17).결론 유선인계세포암침습성강,수체양성솔고,차치료후역출현복발전이,예후차.
carcinoma (SRCC) of the breast.Methods The clinical and pathologic data of 17 SRCC of the breast were analyzed retrospectively.Results Breast SRCC accounted for 2-4.5％ of all breast cancer patients.I0 (58.8％) patients suffered from lymph node metastasis at admission,the positive rates of estrogen receptor(ER) and progesterone receptor (PR) were 71.4％ (10/14) and 64.9％ (9/14) respectively.With a follow-up time varying from 8 months to 11 years recurrence or metastasis were found in 7 patients,another 3 patients were found having distant metastasis at admission.Bone metastasis (8 patients) was most common.Treatments of breast SRCC were analogous to breast cancer at the same stage,sixteen cases were treated with surgery and 14 cases with chemotherapy.The 3' and 5' year disease-free survival rates were 50.3％ (7/17) and 23.0％ (5/17) respectively.With a mean follow-up time of 57 months,the mortality was41.2％ (7/17).Conclusions SRCC of the breast is highly invasive,with high rate of positive receptors and recurrence,and poor patients' survival.